Cargando…
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug design based on distinct signaling pathways in this disorder is only now emerging. Here we...
Autores principales: | Nygaard, Haakon B, van Dyck, Christopher H, Strittmatter, Stephen M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978417/ https://www.ncbi.nlm.nih.gov/pubmed/24495408 http://dx.doi.org/10.1186/alzrt238 |
Ejemplares similares
-
Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons
por: Um, Ji Won, et al.
Publicado: (2012) -
Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy
por: Tang, Si Jie, et al.
Publicado: (2020) -
Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions
por: Matrone, Carmela, et al.
Publicado: (2020) -
Fyn Kinase Is Required for Optimal Humoral Responses
por: Chaimowitz, Natalia S., et al.
Publicado: (2013) -
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)